Successful macular hole closure

Article

It is not necessary for patients to remain face-down for more than 24 hours to ensure successful macular hole closure, according to study results published online ahead of print by the British Journal of Ophthalmology.

It is not necessary for patients to remain face-down for more than 24 hours to ensure successful macular hole closure, according to study results published online ahead of print by the British Journal of Ophthalmology.

Judy E. Kim of the Medical College of Wisconsin, United States and colleagues conducted a 15-month multicentre review of patients (n=53; eyes, n=56) undergoing consecutive stage 3 and 4 macular hole surgeries. Mean preoperative visual acuity was 0.74 logMAR (20/100 Snellen). Surgery was not routinely combined with phacoemulsification, but internal limiting membrane (ILM) peeling, using either SF6 or C3F8 gas tamponade, was conducted in 49 eyes. Of the eyes undergoing surgery, 79% had stage 3 macular holes and 70% were phakic.

Macular hole closure was achieved by just one operation in 93% of eyes (n=52). Mean postoperative visual acuity was 0.41 logMAR (20/50 Snellen). The mean follow-up period was 5.2 months.

Therefore the researchers concluded that - since macular hole closure was achieved in the majority of cases by just one operation with only one day of prone positioning - sustained prone positioning is not necessary for successful hole closure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.